AstraZeneca Confirms Total Voting Rights of 1.55 Billion Shares

AstraZeneca ( (GB:AZN) ) has issued an announcement.

AstraZeneca has confirmed that, as of 31 December 2025, its issued share capital with voting rights consists of 1,550,907,927 ordinary shares, with no shares held in treasury, establishing the total number of voting rights at the same figure. This disclosure, made under UK Financial Conduct Authority transparency rules, provides shareholders and market participants with the reference denominator needed to assess and report any holdings or changes in holdings, supporting regulatory compliance and ensuring clarity around AstraZeneca’s equity base and governance structure.

The most recent analyst rating on (GB:AZN) stock is a Sell with a £105.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.

Spark’s Take on GB:AZN Stock

According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.

AstraZeneca’s strong financial performance and positive earnings call are the most significant factors driving the score. The company’s strategic expansions and product approvals further enhance its outlook. However, the high valuation and moderate technical indicators slightly temper the overall score.

To see Spark’s full report on GB:AZN stock, click here.

More about AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, UK, specialising in the discovery, development and commercialisation of prescription medicines in oncology, rare diseases and broader biopharmaceuticals, including cardiovascular, renal and metabolism, and respiratory and immunology therapies. Its medicines are sold in more than 125 countries and used by millions of patients worldwide.

Average Trading Volume: 2,122,431

Technical Sentiment Signal: Strong Buy

Current Market Cap: £213.8B

Find detailed analytics on AZN stock on TipRanks’ Stock Analysis page.